Advertisement

Topics

Ziarco Pharma Ltd. Company Profile

14:45 EDT 26th March 2019 | BioPortfolio

Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting dermatological and inflammatory diseases. ZPL-389, the Company’s lead compound, is an oral histamine H4 receptor antagonist, currently in two Phase 2a studies: the first in atopic dermatitis is fully recruited and will read out in Q2 2016; and the second has been initiated in moderate to severe psoriasis patients and is expected to be fully recruited in Q1 2017.


News Articles [680 Associated News Articles listed on BioPortfolio]

Deals and M&As this week: LEO Pharma, Valeo Pharma, Allergan

LEO Pharma and MorphoSys have formed a strategic partnership to develop peptide-derived therapeutics. LEO Pharma will select lead molecules using...Read More... The post Deals and M&As this week:...

M&As this week: Sun Pharma, Genentech, CVS Health

Sun Pharma has signed a definitive agreement to acquire Pola Pharma for $1m. The acquisition is part of Sun Pharma’s...Read More... The post M&As this week: Sun Pharma, Genentech, CVS Health ap...

EQT offers to buy Karo Pharma for $654m

Karo Pharma develops and markets products for pharmacies and also directly to the healthcare sector. The specialty pharma company is said to have a strong presence in the The post EQT offers to buy K...

FSD Pharma forms new alliance for pharma-grade cannabinoids

Canada-based FSD Pharma has signed a non-binding letter of intent (LOI) with algae technology company Solarvest BioEnergy for the development...Read More... The post FSD Pharma forms new alliance for ...

Deals this week: Zealand Pharma, Fulcrum Therapeutics, Forendo Pharma

Zealand Pharma has sold its future royalty streams and potential commercial milestones for Soliqua® 100/33/Suliqua® and Lyxumia®/Adlyxin® to Royalty Pharma...Read More... The post Deals this week:...

Alizé Pharma 3 to Build Biopharmaceutical Company Focused on Rare Endocrine and Metabolic Diseases

NewsAlizé Pharma 3 is the third venture within the Alizé Pharma organization, whose first two companies were acquired by Jazz Pharmaceuticals in 2016 and Millendo Therapeutics in 2017.

Sun Pharma to buy Japan’s Pola Pharma

Sun Pharma said it will acquire Japan-based Pola Pharma for around $1 million to strengthen its global dermatology presence.

FSD Pharma: Tenbagger oder Rohrkrepierer?

FSD Pharma ist das Mutterunternehmen der FC Pharma Inc, welche ein lizensierter Marihuana Hersteller aus Kanada ist. Das Unternehmen ist auf die Produktion von Cannabis für den medizinischen Gebrau.....

Drugs and Medications [53 Associated Drugs and Medications listed on BioPortfolio]

Fluoride [mayne pharma inc]

Fluoride Chewable Tablets 0.5 mg

Fluoride [mayne pharma inc]

Fluoride Chewable Tablets 1 mg

Urea [mayne pharma inc.]

Rx Only 45% Urea Nail Gel In a vehicle containing Camphor, Eucalyptus Oil and Menthol )

Eloxatin [aventis pharma ltd.]

NA

Ribavirin [aurobindo pharma limited]

NA

PubMed Articles [19 Associated PubMed Articles listed on BioPortfolio]

Establishing and Maintaining a Robust Sample Management System.

This paper has been written by the SLAS Sample Management Special Interest Group to serve as a guide to the best practices and methods in establishing and maintaining a high-quality sample management ...

Disease awareness advertising (DAA) in emerging economy: A comparison between views of consumers and pharmaceutical professionals.

Research on effectiveness of DAA is limited. Existing researches explore impact of DAA only on relationship between drug manufacturers and consumers. However, in reality, pharma marketing revolves aro...

21 Century Citizen Pharma: The FDA & Patient-Focused Product Development.

Perpetual debate regarding the delicate balance between access and innovation and the protection of the public health and safety dominate discussions of the United States Food and Drug Administration ...

CVS and the $100,000 QALY.

The PBM unit of the health giant CVS decided that any new drug exceeding $100,000 per quality-adjusted life year (QALY) may be excluded from the formularies that are maintained by its clients. Patient...

The Common Pharmaceutical Market of the Eurasian Economic Union: A Regulatory Review.

According to the Treaty on the Eurasian Economic Union, a common pharmaceutical market was supposed to become operational on January 1, 2016. Nevertheless, the responsible parties did not meet the dea...

Clinical Trials [88 Associated Clinical Trials listed on BioPortfolio]

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)

The present clinical trial will be conducted in order to compare the bioavailability of rivastigmine and to assess bioequivalence at steady-state of the Test product RID-TDS 9.5 mg/24 h (L...

To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions

To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.

Pharma-Pen (Formerly Innoject) Auto-Injectory TIV

The purpose of this study is to evaluate the safety, effectiveness, and tolerability, of the Pharma-Pen(TM) intramuscular (IM) and subcutaneous (SC) auto-injector systems used by untrained...

A Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Cefadroxil from Duricef 1 gm Film Coated tablets(Smthkline Beecham Egypt,LLC aff...

Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition

The primary objective is to determine clinical bioequivalence of Amphotericin B liposome for injection of Auromedics Pharma LLC, USA and AmBisome (Amphotericin B) liposome for injection of...

Companies [802 Associated Companies listed on BioPortfolio]

Ziarco Pharma Ltd.

Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting dermatological and inflammatory diseases. ZPL-389, the Company’s lead compound, ...

Ziarco

Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting inflammatory and allergic diseases. The company’s product pipeline includes ZPL-...

H3 Pharma Incorporated

H3 Pharma Inc. is a Venture Pharma focusing on the development of human therapeutic products oriented towards age-related disorders. At H3 Pharma, we aim to be the best at identifying, evaluating and ...

LEO Pharma Inc.

LEO Pharma Inc. is headquartered in Parsippany, New Jersey, and is the U.S. affiliate of Denmark-based LEO Pharma A/S, a global leader in dermatology and critical care with more t...

Laurantis Pharma Oy

Laurantis Pharma Oy is a privately held specialty pharmaceutical company based in Finland. Laurantis Pharma Oy was formed in 2010 through the merger of two independent companies, ...

More Information about "Ziarco Pharma Ltd." on BioPortfolio

We have published hundreds of Ziarco Pharma Ltd. news stories on BioPortfolio along with dozens of Ziarco Pharma Ltd. Clinical Trials and PubMed Articles about Ziarco Pharma Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ziarco Pharma Ltd. Companies in our database. You can also find out about relevant Ziarco Pharma Ltd. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Dermatitis
Dermatitis means an inflammation of the skin. Contact dermatitis is a term used when this inflammation is caused by contact with something in the environment. The changes of dermatitis seen in the skin take the form of eczema; hence it may sometimes be r...

Psoriasis
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...


Corporate Database Quicklinks



Searches Linking to this Company Record